Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | -0.90% | 168.39 | 1.3% | $496.78m | |
| BIIB | Biogen Inc. | 0.65% | 230.76 | 1.3% | $480.84m | |
| CELG | Celgene Corporation | -0.62% | 94.83 | 1.3% | $471.13m | |
| GILD | Gilead Sciences, Inc. | -0.75% | 65.86 | 0.9% | $453.88m | |
| ILMN | Illumina, Inc. | -2.29% | 300.59 | 3.5% | $305.96m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.78% | 302.57 | 2.6% | $276.84m | |
| A | Agilent Technologies, Inc. | -0.29% | 68.91 | 1.6% | $198.64m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -1.78% | 165.73 | 1.9% | $176.80m | |
| EXAS | Exact Sciences Corporation | -0.16% | 96.04 | 25.3% | $171.72m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -2.80% | 127.23 | 2.0% | $150.06m | |
| BMRN | BioMarin Pharmaceutical Inc. | -2.31% | 86.66 | 4.3% | $118.53m | |
| SRPT | Sarepta Therapeutics, Inc. | -3.37% | 117.57 | 14.7% | $114.20m | |
| INCY | Incyte Corporation | -0.48% | 76.83 | 2.5% | $105.26m | |
| IONS | Ionis Pharmaceuticals, Inc. | 0.09% | 67.46 | 8.2% | $98.12m | |
| ALNY | Alnylam Pharmaceuticals, Inc | -2.49% | 65.86 | 9.2% | $93.34m |
Company Profile
EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses in the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.